Amarin Corporation plc. is a rapidly growing, innovative pharmaceutical company focused on developing therapeutics to improve cardiovascular health. Amarinâs product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. VascepaÂŽ (icosapent ethyl) is Amarin's first FDA-approved drug and is available by prescription. Amarin is headquartered in Dublin, Ireland. Amarin's U.S. office is in Bedminster, New Jersey. Amarin is listed in the U.S. on NASDAQ (symbol: "AMRN"). Source
No articles found.
Pulmatrix is a clinical stage biopharmaceutical company developing innovative inha...
Pulmatrix is a clinical stage biopharmaceutical...
Sunesis is a biopharmaceutical company focused on the development and commercializ...
Sunesis is a biopharmaceutical company focused ...
TCR² is an innovative immunotherapy company developing the next generation of T c...
TCR² is an innovative immunotherapy company de...
Galapagos develops therapies with proprietary, novel modes-of-action. Filgotinib, ...
Galapagos develops therapies with proprietary, ...
NeurMedix, Inc., is a clinical-stage biotechnology company that engages in develop...
NeurMedix, Inc., is a clinical-stage biotechnol...
Syndax Pharmaceuticals, Inc. is a late-stage biopharmaceutical company focused on ...
Syndax Pharmaceuticals, Inc. is a late-stage bi...
Arena Pharmaceuticals is driven to deliver novel, transformational medicines with ...
Arena Pharmaceuticals is driven to deliver nove...
Join the National Investor Network and get the latest information with your interests in mind.